Camden National Corp
Banking
Camden National Corp (CAC) Stock News
The latest CAC headlines and market coverage — 6 recent stories, updated throughout the day.
- Zacks Investment Research·
Zacks Industry Outlook Highlights CACI International and PDF Solutions
The Computer Services industry faces macroeconomic headwinds and carries a Zacks Industry Rank #187 (bottom 24%), with analyst earnings estimates down 0.4% since January 2026. However, AI-driven digital transformation and growing cybersecurity demands present opportunities. CACI International and PDF Solutions are highlighted as stocks to watch, benefiting from defense spending, AI adoption, and semiconductor investment tied to data center buildouts.
- GlobeNewswire Inc.·Neutral
GENFIT va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
GENFIT, a biopharmaceutical company focused on rare liver diseases, has been included in the Euronext Paris indices CAC Mid 60 and SBF 120, effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its reputation among institutional investors. The company continues to develop therapeutic and diagnostic solutions, including the FDA-approved Iqirvo® for primary biliary cholangitis.
- GlobeNewswire Inc.·Neutral
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
GENFIT, a biopharmaceutical company focused on rare liver diseases, has been admitted to the Euronext Paris CAC Mid 60 and SBF 120 indices effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its profile among institutional investors.
- Zacks Investment Research·
Why Is CACI International (CACI) Up 0.2% Since Last Earnings Report?
The article discusses various investment opportunities across sectors including robotics and AI, oil and natural gas, aerospace, employment trends, and biotech. It highlights earnings estimate increases for an oil and gas company, market cap movements for a space company, job growth in leisure and hospitality, and provides stock screening tools for investors seeking diversified exposure to emerging themes.
- GlobeNewswire Inc.·
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics presented additional clinical trial results for aficamten (MYQORZO) at the ESC Congress 2026. ACACIA-HCM data showed aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients beyond exercise capacity improvements. MAPLE-HCM analysis demonstrated aficamten outperformed metoprolol across different pre-trial treatment groups in obstructive HCM patients. The company plans to submit a Supplemental New Drug Application for non-obstructive HCM in Q4 2026.
- Zacks Investment Research·
Why CACI International (CACI) is a Top Stock for the Long-Term
Zacks presents its Focus List investment strategy, a curated portfolio of 50 stocks designed to outperform the market over 12 months. The strategy relies on earnings estimate revisions and the proprietary Zacks Rank system. Historical performance shows the Focus List returned 2,519.23% cumulatively since February 1996, compared to the S&P 500's 854.95%. CACI International is highlighted as a Focus List success story, gaining 513.51% since its December 2015 addition.